Plant genetic engineering led to the production of plant-derived mAb (mAb P ), which provides a safe and economically feasible alternative to the current methods of antibody production in animal systems. In this study, the heavy and light chains of human anti-rabies mAb were expressed and assembled in planta under the control of two strong constitutive promoters. An alfalfa mosaic virus untranslated leader sequence and Lys-Asp-Glu-Leu (KDEL) endoplasmic reticulum retention signal were linked at the N and C terminus of the heavy chain, respectively. mAb P was as effective at neutralizing the activity of the rabies virus as the mammalianderived antibody (mAb M ) or human rabies Ig (HRIG). The mAb P contained mainly oligomannose type N-glycans (90%) and had no potentially antigenic ␣(1,3)-linked fucose residues. mAb P had a shorter half-life than mAb M . The mAb P was as efficient as HRIG for post-exposure prophylaxis against rabies virus in hamsters, indicating that differences in N-glycosylation do not affect the efficacy of the antibody in this model.
M
ore than 10 million people annually receive rabies virus prophylaxis in the form of equine anti-rabies immunoglobluin (ERIG) or human anti-rabies Ig (HRIG), together with rabies vaccine (1) . However, the world shortage of these immunoglobulins, as well as the risk of both adverse reactions associated with ERIG and the high cost of HRIG, has hampered global efforts to provide a post-exposure prophylaxis against rabies (2) .
Transgenic plants have proven to be an efficient production system for the expression of functional therapeutic proteins (3) . Plant-derived monoclonal antibodies (mAb P ) have the same advantages, namely, the lack of animal pathogenic contaminants, low cost of production, and ease of agricultural scale-up compared with the conventional fermentation methods. Since the initial report of functional mAbs expressed in transgenic plants (4) , therapeutic and diagnostic mAbs P have been successfully produced in transgenic tobacco, soybean, alfalfa (5) (6) (7) (8) , and other plants (3) . Two mAbs P have recently been used for topical passive immunization against Streptococcus mutans and herpes simplex virus in animals (5, 6) . To date, no study has reported the use of systemic administration of mAb P to provide immunoprotection.
Differences in posttranslational modifications, such as glycosylation, have been shown to influence the properties of plantderived proteins (3, 9, 10) . In plants, N-linked glycans may contain antigenic (11) and͞or allergenic (12) ␤(1, 2)-xylose (Xyl) residues attached to the ␤-linked mannose (Man) of the glycan core and ␣(1,3)-fucose (Fuc) residues linked to the proximal GlcNAc that are not present on mammalian glycans. Plant glycans do not contain sialic acid residues, and mAbs P do not require these residues for successful topical passive immunization (5, 6) .
Glycosylation processing in the endoplasmic reticulum (ER) is conserved amongst almost all species and restricted to oligomannose (Man [5] [6] [7] [8] [9] GlcNAc 2 ) type N-glycans, whereas the Golgigenerated processing to hybrid and complex type glycans is highly diverse (13) . When attached to the C terminus, the ER retrieval motif KDEL (Lys-Asp-Glu-Leu) allows glycoproteins to be retained in, or returned to, the ER. Although there are exceptions (14) , in general, glycans attached to proteins containing a C-terminal KDEL sequence would be expected to be restricted mainly to the oligomannose type (13, 15, 16) . ER retention of proteins in transgenic plants usually improves the production levels (9, 17) . However, because glycan processing can affect the stability of antibodies (18) , it is unclear whether an mAb P with modified glycan structures would be active and able to confer effective systemic post-exposure prophylaxis.
Here, we have expressed and characterized the human antirabies mAb derived from transgenic tobacco plants and demonstrated its effectiveness in vivo. The mAb P was compared with the human mAb SO57 (mAb M ) expressed in murine͞human hybridoma cell lines (19, 20) and͞or commercial HRIG for rabies virus neutralization activity, protein stability, N-glycan processing, and the efficacy of rabies virus post-exposure prophylaxis in exposed animals.
Materials and Methods
Construction of Plant Transformation Binary Vector. cDNA fragments encoding for mAb SO57 light chain (LC, 729 bp; GenBank accession no. AY172960) and heavy chain (HC, 1,431 bp; GenBank accession no. AY172957) (20) were arranged into a pBI121 binary vector (CLONTECH) as follows. The HC was amplified with primers containing NcoI and XbaI sites (5Ј-cgccatggactggacctggaggttc-3Ј and: 5Ј-gctctagattagagctcatctttgtgat-ggtgatggtgatgtttacccggggacagggag-3Ј, containing the KDEL ER retention signal) and placed with the alfalfa mosaic virus untranslated leader sequence (AMV) of RNA4 (21) under the control of the cauliflower mosaic virus 35S promoter with duplicated upstream B domains (Ca2p) (22) into the pUC9-based vector. The LC was amplified by using primers containing BamHI and PstI sites (5Ј-cgggatccatgagtgtccccaccatggcc-3Ј and 5Ј-cgctgcagctatgaacattctgtaggggc-3Ј) and subcloned into the corresponding sites of pGEM T vector (Promega) between potato proteinase inhibitor II promoter (Pin2p) and its terminator (23) . The HC and LC expression cassettes were consequently transferred as HindIII-EcoRI fragment (HC) and HindIII fragment (LC) into the plant binary vector pBI121 to yield pBIRA-57 (Fig. 1A) SDS͞PAGE and Protein Blot Analysis. One gram of leaf tissues was ground in liquid nitrogen with 100 l of extraction buffer (50 mM Tris, pH 7.5, 250 mM sucrose) containing Complete inhibitor mixture (Roche Diagnostics). Forty micrograms of soluble protein was resolved on 12% SDS͞PAGE and transferred to Immobilon-P (Millipore) by using a miniProtean II system (Bio-Rad). Goat anti-human antibody [Fc␥ and F(abЈ) 2 fragment-specific] conjugated to horseradish peroxidase (Jackson ImmunoResearch) was used to detect HC and LC, respectively, by using SuperSignal (Pierce). mAb M was used as a positive control (20) .
Purification of Plant-Derived Antibodies. Soluble protein extracts were one-step affinity purified by using protein A agarose matrix (Invitrogen) overnight (4°C) and either applied for HPLC analysis of N-linked glycans or an extra purification step was carried out on protein G column (Pierce) according to the manufacturer's recommendations, dialyzed in 1ϫ PBS buffer and brought to the appropriate concentrations with Millipore spin-columns [10,000 nominal molecular weight limit (NMWL)]. Preparations were either used immediately or stored at Ϫ80°C as aliquots.
In Vitro Rabies Virus Neutralization Assay. The rapid fluorescent focus inhibition test (RFFIT) was carried out with some modifications (19, 25) . Three-fold serial dilutions of mAb P , mAb M , and HRIG (Imogam Rabies-HT, Aventis Pasteur, Swiftwater, PA) were incubated with rabies virus cell culture adapted strains (CVS-11 and CVS-N2c) and dog street rabies virus (DRV-4) for 60 min at 37°C. The mixture of antibody and virus was used to infect baby hamster kidney (BHK-21) cells. After incubation in a 96-well flat-bottom plate for 40 h at 37°C, the cells were washed, fixed, and stained with the FITC-labeled anti-rabies reagent and examined under a fluorescence microscope (25) .
HPLC Analysis of N-Linked Glycans. The HC and LC of mAb P and mAb M proteins were separated on an SDS͞PAGE. N-linked glycans were released from gel slices by incubation with peptide N-glycosidase (PNGase) F and PNGase A (14, 26) . Labeling, HPLC, and simultaneous exoglycosidase sequencing of the released glycan pool were performed (27) (28) (29) (30) (31) (32) . Exoglycosidases were used at the following concentrations: Arthrobacter ureafaciens sialidase (ABS, EC 3.2.1.18), 1-2 units͞ml; almond meal ␣-fucosidase (AMF, EC 3.2.1.111), 3 milliunits͞ml; bovine testes ␤-galactosidase (BTG, EC 3.2.1.23), 1-2 units͞ml; Streptococcus pneumoniae ␣-hexosaminidase (SPH, EC 3.2.1.30), 120 units͞ ml; and Jack Bean ␣-mannosidase (JBM, EC 3.2.1.24), 100 milliunits͞ml. Glycopro Glucosaminidase (GluH, Prozyme, San Leandro, CA) was used as recommended by the manufacturer. ments). The nitrogen laser (337 nm, 3 ns pulse width) pulse rate was 10 Hz, and a small bias voltage (2.5-30 V) was applied to the MALDI sample plate, depending on the mass of the analyte under investigation. After ionization, ions were extracted by a negative potential (Ϫ10 kV); trapped by application of a retarding potential to the end-cap and an rf potential (500 kHz) to the ring electrode of the ion trap; and cooled by using helium (6 ϫ 10 Ϫ3 Torr). Fragmentation was induced by resonant excitation after application of a supplementary AC potential to the end cap electrodes. Product ions from the molecular or fragment ions were extracted into the TOF analyzer with an accelerating voltage of 10 kV. The TOF was externally calibrated by using fullerite deposited directly onto the sample stage. Glycans, subjected to fragmentation, were previously digested with A. ureafaciens sialidase, and the sample target was prepared as above.
In Vivo Half-Life of mAbs. Five micrograms of mAb P or mAb M in 100 l of 1ϫ PBS buffer were injected i.p. into 10 and 7 BALB͞c mice (female, 6-8 wk; The Jackson Laboratory), respectively. Blood samples were collected from the orbital sinus on days 1, 2, 3, 4, 7, 8, and 10 after injection; each mouse was bled twice during the entire time period. Serum levels of mAb P and mAb M were detected by ELISA as described above. 
Results
Tobacco transgenic lines were generated by Agrobacteriummediated transformation with a binary vector carrying both the heavy chain (HC) and light chain (LC) of human mAb SO57 (Fig. 1) . Fig. 1 A shows the construct arrangement. The HC cDNA was fused with AMV at its 5Ј end and the KDEL retention signal at its 3Ј end and placed downstream of the enhanced cauliflower mosaic virus 35S promoter (Ca2p). The LC was placed under the control of the strong Pin2 promoter. PCR analysis of transgenic plants generated from independent transformation events revealed the presence of both HC and LC in seven transgenic lines (R5, R8, R9, R11, R12, R13, and R14; Fig.  1B ). Protein expression analysis by ELISA confirmed that human mAb SO57 is expressed in the same transgenic lines (Fig.  1C) . Transgenic line R8, with the highest absorbance level (Ͼ0.35), was selected for further studies. Transgenic plant R8 did not differ morphologically from the WT plant (Fig. 1D) and retained the same level of protein expression over several generations (data not shown).
Both HC and LC were identified in the soluble protein extracts from the transgenic plant R8 leaf tissue as major bands migrating at the expected molecular masses, 50 kDa and 25 kDa, respectively ( Fig. 2A) . HC was readily detected by anti-human Fc␥ fragment-specific antibody in both mAb M and R8 (Fig. 2 A  Center) . Two lower molecular mass bands observed in mAb M ( Fig. 2 A, asterisks) are most likely to be HC proteolytic degradation products. LC was detected by anti-human F(abЈ) 2 fragment-specific antibody. The HC band was detected in mAb M , whereas only LC was detected in R8 together with a lower molecular mass band probably resulting from proteolytic degradation ( Fig. 2 A Right, diamond) . The expression level of mAb P in R8 plants was calculated as 3 g͞g of fresh leaf weight (0.07% of total soluble protein), consistent with ELISA results (data not shown). Further purification of antibody derived from plant leaf extracts (mAb P ) and from hybridoma supernatants (mAb M ) using a single-and͞or double-step purification with protein A and protein G yielded high quality protein products (HC and LC only). Fig. 2B shows the results of the single-step (protein A) purification.
In vitro comparison of the neutralizing activity of mAb P , mAb M , and HRIG against cell culture-adapted and a street rabies virus (Table 1) indicated that mAb P was as active against *Virus-neutralizing antibody (VNA) titer was determined as described (35) . † CVS-11 and CVS-N2c are cell culture-adapted virus strains, and DRV-4 is a dog street rabies virus.
the cell culture-adapted virus strain CVS-11 as mAb M and HRIG, and more active than HRIG against the CVS-N2c strain. MAb (Fig. 3) were confirmed by exoglycosidase digestions and were consistent with MALDI-TOF mass spectrometry results (data not shown).
For mAb P (Fig. 3 Upper), 90% of the total glycan pool consisted of oligomannose-type oligosaccharides (peaks 3-6 contained Man 6 -9 GlcNAc 2 , respectively). The remaining two peaks (1 and 2) corresponded to GlcNAc 2 Man 3 GlcNAc 2 (4.3%) and GlcNAc 2 Man 3 (Xyl)GlcNAc 2 (5.7%). No Fuc or Gal residues were found on any plant-derived glycan structures. In contrast, the mAb M (Fig. 3 Lower) displayed a range of complex glycans, most of which (95.4%) contained a core ␣(1,6)-Fuc and outer-arm Gal and about half contained sialic acid (peaks 7-12 and 14 -17). Twelve percent of glycans (within peaks 13 and 15-17) contained additional Gal residues. This additional Gal was identified as the terminal monosaccharide in Gal␣1-3Gal␤1-4GlcNAc-R, because it was digested with coffee bean ␣-galactosidase that releases only ␣-Gal-linked monosaccharides. Consistent with the HPLC elution position and the exoglycosidase digestions, MALDI mass spectrometry using a tandem ion trap-TOF instrument also located the extra Gal to the nonreducing terminus of one of the antennae of the glycan with the composition Hex 6 HexNAc 4 dHex 1 (Gal 3 GlcNAc 4 Man 3 Fuc 1 , [M ϩ Na] ϩ at m͞z 1971.7). Two successive stages of fragmentation (MS 3 spectrum) indicated that the structure of the ion at m͞z 550.2, derived from this antenna, was Hex-Hex-HexNAc (data not shown). This Gal residue is therefore the commonly known ␣-Gal epitope of murine origin that is antigenic to humans (34) .
In vivo stability of mAb P and mAb M was analyzed in a comparative clearance test in which mice were injected i.p. and blood samples were collected for up to 10 days. In an ELISA to determine the levels of these antibodies in serum from mice, mAb P was barely detectable 10 days after injection, whereas mAb M was still abundant (Fig. 4) . The efficacy of mAb P in post-exposure prophylaxis was examined in hamsters injected with rabies virus of coyote origin (Table 2 ). In this in vivo protection assay, all untreated control hamsters succumbed to fatal rabies virus encephalitis, as did those animals that received HDCV vaccine only. The survival rate for hamsters that received 3 IU of mAb P or 2 IU of HRIG without administration of HDCV vaccine was Ϸ50%, whereas the rate was decreased in hamsters receiving lower mAb P doses of 0.4 and 0.7 IU alone. The survival rate remained high (8 of 9) when mAb P at any concentration level was administered together with HDCV vaccine (Table 2) .
Discussion
Our present data demonstrate that the plant-expressed human mAb (mAb P ), containing mainly oligomannose type N-glycans, has anti-rabies virus-neutralizing activity comparable to that of its mammalian-derived counterpart, and an efficacy in rabies post-exposure prophylaxis comparable with that of HRIG. The expression level and appropriate posttranslational events (correct folding, glycosylation, and subcellular targeting) are important factors for the effectiveness of antibodies produced in plants (7, 10, 17, 35) . In our study, these factors were optimized by the combination of gene regulatory elements in a plant binary vector. Two different strong constitutive promoters (Pin2p and Ca2p) controlling the expression of LC and HC of the human antibody, respectively, and a translation AMV activator and ER retention signal KDEL, fused to HC, were combined to avoid homology-based gene silencing (36) , aimed to increase HC expression levels (23) and to induce compartment-specific accumulation, respectively (5, 6, 8) . The human antibodies were expressed (0.07% of total soluble protein) and fully assembled in plants without any gene silencing through two generations of the R8 transgenic line with single gene integration (data not shown). These data indicate the feasibility of the construct arrangements to express and assemble functional mAbs in plants.
In contrast to mAb M , which contains 17 complex N-glycans in the conserved glycosylation site on each HC, the mAb P modified to contain a KDEL sequence displays mainly oligomannose-type N-glycans (90%). A previous report indicated that mAb P (lacking an ER retention signal) contains a greater diversity of N-glycan structures (37) . This result is predictable because, in the absence of a KDEL sequence, mAb P would be expected to be transported to the Golgi apparatus where oligomannose-type glycans can be processed to complex type structures (13) . The presence of Man 6 -9 GlcNAc 2 (90%), GlcNAc 2 Man 3 GlcNAc 2 (4.3%), and GlcNAc 2 (Xyl)Man 3 GlcNAc 2 (5.7%) glycans in mAb P indicates that most (90%) of mAb P ͞KDEL did not pass further along the secretory pathway than the cis-Golgi stack, from which it was probably retrieved and returned to the ER (15, 16) . As a result, the modified mAb P did not contain glycans with the plant-specific ␣(1,3)-linked Fuc residues, minimizing the risk of immunogenic and allergenic reactions to this epitope in humans (11) . The ␣(1,3)-linked Fuc residue is recognized by both IgG and IgE (38) . If present, the Xyl residue that is ␣(1,2)-linked to the ␤-linked core Man of the sugars attached to mAb P forms part of the anti-␣(1,3)-linked Fuc antibody epitope, but does not, on its own constitute a potent epitope (38) . Moreover, the Xyl-containing glycans in mAb P also contain an ␣(1,3)-antenna, and, on these grounds too, the Xyl is unlikely to bind IgE (12) . In contrast, ␣-Gal residues are potent antigens (34) . The terminal ␣-Gal residues on the sugars attached to mAb M are likely to be accessible even in the context of the IgG CH2 domains in which the glycans are sequestered. Interestingly, the detection of the ␣-Gal residue provides evidence that the hybridoma cell line had used the murine rather than the human glycosylation machinery. mAb P had similar in vitro neutralizing activity against cell culture-adapted virus strains and a street virus, compared with the mAb M . Neutralization depends on blocking of binding sites on the virion and may be mostly mediated by steric hindrance resulting from the relatively large size of the antibody molecule (39) . The altered glycosylation on the CH2 domain of antibodies does not affect their affinity for antigen (18, 40) . The altered glycosylation of mAb P with oligomannose N-glycans might reduce the affinity for an Fc receptor and be deficient in antibody-dependent cell-mediated cytotoxicity (41) , which is involved in antiviral activity (40, 42) . In vivo efficacy of mAb P for post-exposure prophylaxis was similar to that of HRIG. mAb P with oligomannose-type N-glycans was rapidly cleared in vivo compared with mAb M . The shorter half-life of mAb P is predictable, because oligomannose-type N-glycan structures would be expected to lead to an increased clearance rate through binding of the antibodies to Man receptors such as the macrophage Man receptor in liver (41, 43) . However, the shorter half-life of the mAb P -containing oligomannose-type glycans did not adversely affect the immunological protection against rabies for post-exposure prophylaxis. The dual effect of rabies postexposure treatment with both antibody and vaccine in mammals may occasionally lead to interference between passive and active immunization because of larger persistence of the antibody in the circulation (44) (45) (46) . Thus, the shorter half-life of this mAb P , if confirmed in humans, may offer a certain advantage to the current commercial antibody-vaccine prophylaxis because there will be less probability of interference between the passive and active immunity.
Our findings indicate that the modified N-glycosylation pattern of mAb P does not affect the neutralizing and protective efficacy of post-exposure prophylaxis against rabies virus in hamsters. mAb P was found to be as efficient as HRIG. The main benefits of using plant as an expression system include, but are not limited to, the absence of antigenic and͞or allergenic epitopes, and ample protein yield. Further studies are needed to determine the efficacy of the mAb P against other lyssavirus candidate infections in different animal models, including non-human primates. There is a dramatic shortage of rabies antibodies worldwide; hence, production of inexpensive and safe plant-derived mAb should be useful in post-exposure prophylaxis.
